Fate Therapeutics Inc.

FATE

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Redmile Group

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Redmile GroupNEWFeb 17, 2026

Shares: 12,872,946Value: $12.6M

# Signal Note: Redmile Initiates FATE Position Redmile's $12.6M entry into Fate Therapeutics suggests conviction in the company's engineered iPSC-derived NK cell platform, likely ahead of clinical readouts for its lead program FT500 (off-the-shelf NK cells for solid tumors and hematologic malignancies) expected in H1 2024. Jeremy Green's healthcare crossover focus typically targets inflection points, indicating he sees near-term value catalysts in the company's development pipeline or potential partnership activity.

More FATE Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ATRA1 fund IMNM1 fund KRYS1 fund ADCT1 fund KLRS1 fund CLDX1 fund CBLL1 fund NGNE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: